Outcome problems are not confined to clinician or patient observed scales. As we were prompted recently in the MSJ, there are numerous traps for the unwary, with so-called objective measures such as MRI in progressive MS. 5 Brain atrophy is of course very current in phase 2 trials in progressive MS, but there are a number of issues which will add error to the result and therefore impede the outcome measurement. We are reminded of the effects of age, hydration status and drug-induced pseudoatrophy. Moreover as a worked example, the tool that is used, MRI, in the context of a scanner upgrade can change the atrophy rate by about 1.5%. 5 Frightening, when considering a background rate of whole brain atrophy in progressive MS of about 0.5%/year. The confounding effects on more advanced MRI parameters, particularly in the heterogeneous multi-site environments of clinical trials will of course magnify the problem.
Moreover, the difficulties are not just confined to measuring human beings with progressive MS. In the parallel world of animal models, a similar suite of concerns and worries exist with outcomes and their measurement. In one survey of 2600 reports, which included Experimental Autoimmune Encephalomyelitis (EAE), a blinded assessment of outcome was reported in about 30% of studies, with the rate for EAE being only 20%. 6 I think it is clear from what has been said above, that from the basic to the complex outcome, from animal to human, in trying to solve a problem such as progressive MS, there is plenty that can and does go wrong. The numerous other hurdles, recruitment, drug choice and trial design, though problematic, are of a lower order of magnitude.
About half of the people living with multiple sclerosis (MS) have progressive MS, in which symptoms worsen gradually over time, independent of clinical relapses. The failure of the majority of clinical trials in progressive MS has raised the question: are the therapies really ineffective, or have we simply been unable to measure their benefit? For the past quarter century, Expanded Disability Status Scale (EDSS) 1 has been the standard disability measure in most MS clinical trials, scoring MS impairment between 0 and 10. Derived originally from a spinal cord injury scale, it is no surprise that the EDSS is heavily driven by spinal cord functions. Ambulation is the primary driver of overall EDSS in RJ Fox the upper half of the scale's range, which is where most people with progressive MS score. In the late 1990s, the multiple sclerosis functional composite (MSFC) was developed to replace the EDSS. 2 The MSFC combines measures of ambulation, arm, and cognitive function and has been further refined over recent years with the addition of a visual scale and replacement of the cognitive scale. Regulatory acceptance of the MSFC has been slow, and another disability measure is under development through the MS Outcomes Assessment Consortium. 3 Although these advancements in outcome metrics are more recent, the failure of previous progressive MS trials seems unlikely to be secondary to an insufficiently sensitive metric. Although EDSS doesn't capture well all of the components of advanced disability, it still captures well the important function of ambulation. The majority of people with progressive MS will manifest their progressive disability through worsening in ambulation, including simple ambulation functions such as transferring from wheelchair. Particularly when EDSS was combined with other measures to form a composite, most trials have shown a very large proportion of participants with progression over the course of the trial. For example, the INFORMS (Oral Fingolimod in primary progressive multiple sclerosis) trial in primary progressive MS found that 70% of subjects demonstrated sustained disability progression by the end of the trial. 4 Clearly, a sufficient proportion of subjects demonstrated progression to measure the impact of the intervention. Additionally, despite several advantages, MSFC has not been shown to be more sensitive than EDSS as an outcome in progressive MS clinical trials.
Instead of shortcomings in the clinical metric, the failure in progressive MS trials seems more likely because of the therapies tested. The majority of progressive MS trials utilized anti-inflammatory therapies. These therapies were successful in reducing inflammation in progressive MS trials: clinical relapses and new lesions on magnetic resonance imaging (MRI) were consistently reduced by anti-inflammatory therapies, even in trials involving people with progressive MS. Unfortunately, these reductions in inflammatory measures were not accompanied by a slowing in disability progression. In progressive MS, there appears to be a dissociation between active, infiltrative inflammation (i.e. clinical relapses and new lesions on MRI) and disability progression, and this dissociation is the likely reason for the failure of so many trials evaluating antiinflammatory therapies. Indeed, when trial enrollment is enriched for active inflammation through the enrollment of younger participants with shorter disease duration, anti-inflammatory therapies can be found to be effective, even when using the traditional EDSS. 5 The failure of most progressive MS trials appears to be driven principally by an incorrect treatment target. Progressive MS-particularly the later stages of progressive MS-is probably not driven by the same infiltrative inflammation which drives the relapsing component of MS. The underlying pathophysiology of progressive MS has not been established, but probably involves different mechanisms from infiltrative inflammation. Neurodegeneration from oligodendrocyte dysfunction, microglial activation, astrocyte dysfunction, loss of vascular integrity, and axonal dysfunction from mitochondrial exhaustion are all pathologic mechanisms hypothesized to drive progressive MS. 6 Several contemporary trials employed treatments that targeted these non-inflammatory mechanisms, and some have found promising results. 7 Another reason for the failure of most progressive MS trials is the lack of a reliable, dynamic biomarker for use in phase II proof-of-concept trials. Without validated biomarkers, it is difficult to choose appropriate interventions for phase III licensing trials. Currently, new lesions on conventional MRI scans are the standard endpoint for phase II trials in relapsing MS, robustly predicting clinical outcome in later phase III trials. 8 Unfortunately, the equivalent biomarker in progressive MS is not clearly established. Wholebrain atrophy is the current standard phase II outcome metric in progressive MS, but is blunt, insensitive, and demonstrates significant biologic variability. The successful development of a more robust biomarker for phase II trials in MS will help select therapies with higher probability of success in phase III trials. 9 As with all diseases, developing more sensitive and dynamic clinical metrics of progression is always encouraged. A more comprehensive characterization of disease progression can better measure the potential benefit of a putative therapy. Furthermore, better selection of participants who are more likely to demonstrate disease progression over the course of the study and thus be contributory to measuring the effect of a therapy will increase the power of the study. However, the primary driver of past failed trials in progressive MS is most likely simply the wrong therapy, which targeted the wrong pathophysiology. By better matching the underlying disease pathophysiology with a putative therapy, and by better selecting therapies through more informative phase II trials paradigms, we will be much more likely to find an effective therapy for progressive MS.
